IMUX

IMMUNIC, INC.
—

Company Information

Company Name
IMMUNIC, INC.
CIK
CIK0001280776
Category
Non-accelerated filer<br>Smaller reporting company
Ticker: Exchange
IMUX: Nasdaq
Fiscal Year End
December 31
Owner Organization
03 Life Sciences
SIC
2834
SIC Description
Pharmaceutical Preparations
Ticker
IMUX

SEC filing data through

Insider Sentiment

Last purchase
2025-06-13
Last sale
—
Shares purchased (TTM)
352,887
Shares sold (TTM)
0
Buy ratio (TTM)100.0%

Institutional Sentiment

As of
2026-06-30
Institutional shares owned
8,438,939
Shares outstanding
42,513,839
Ownership
19.85%

Earnings Market Reaction

Filing date
2026-08-11
Price on filing date
—
1-month reaction
-15.31%
3-month reaction
…
Drift continued4/11 (36%)
Faded / reversed7/11 (64%)

Balance Sheet

Values in millions ($)
Line item2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-30Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only columnTrend
Assets Current
Cash And Cash Equivalents At Carrying Value15518715355514365980974760
Other Short Term Investments----------00
Prepaid Expense And Other Assets Current327455445566
Assets Current158189233960193963851035365
Property Plant And Equipment Net111111111000
Operating Lease Right Of Use Asset101111111111
Assets159190244161214165861045467
Other Assets Noncurrent----------00
Liabilities Current
Accounts Payable Current131110886868753
Accrued Liabilities Current182219191818131614121914
Other Liabilities Current152311111111
Liabilities Current313831302726222323202518
Liabilities Noncurrent
Operating Lease Liability Noncurrent000000000011
Liabilities Noncurrent000000000011
Liabilities323931302826222423212519
Stockholders Equity
Preferred Stock Value000000000000
Common Stock Value000000000000
Additional Paid In Capital800789599597595528526524522520436434
Accumulated Other Comprehensive Income Loss Net Of Tax333334444444
Retained Earnings Accumulated Deficit-675-641-609-589-564-537-511-486-462-440-411-389
Stockholders Equity128151-71034-5184164842948
Liabilities And Stockholders Equity159190244161214165861045467
Preferred Stock Par Or Stated Value Per Share0.000.000.000.000.000.000.000.000.000.000.000.00
Preferred Stock Shares Authorized202020202020202020202020
Preferred Stock Shares Issued000000000000
Preferred Stock Shares Outstanding000000000000
Common Stock Par Or Stated Value Per Share0.000.000.000.000.000.000.000.000.000.000.000.00
Common Stock Shares Authorized500500500500500500500500500500130130
Common Stock Shares Issued141490991099099954
Shares Outstanding141490991099099954

Select a line item above to chart it.

Recent filings

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial

IMMUNIC, INC. (IMUX) — SEC Financial Statements & Analysis

IMMUNIC, INC. (IMUX) is a pharmaceutical preparations company, incorporated in DE. IMMUNIC, INC. trades on Nasdaq as: IMUX. IMMUNIC, INC. (IMUX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, IMMUNIC, INC. carries a market cap of $653.44M, a P/E ratio of -5.86x, a P/B ratio of 5.12x, an enterprise value of $498.34M, and an EV/EBITDA multiple of -4.23x. On profitability, it posts a Return on Equity (ROE) of -138.17% and a Return on Assets (ROA) of -101.15%. Per share, it reports EPS of $-2.62, diluted EPS of $-2.62, free cash flow per share of $-2.07, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 9.55% year-over-year and EPS growth of -65.94% year-over-year. On the balance sheet, it maintains a current ratio of 5.05x, a quick ratio of 4.96x, working capital of $126.57M, a debt-to-equity ratio of 0.25x, a debt ratio of 0.2, free cash flow of $-88.05M (TTM), and net debt of $-155.10M. Figures sourced from SEC EDGAR.

Market Cap
$653.44M
P/E TTM
-5.86x
EPS TTM
$-2.62
P/B TTM
5.12x
ROE TTM
-138.17%
ROA TTM
-101.15%
Debt To Equity
0.25x
Free Cash Flow TTM
$-88.05M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is IMMUNIC, INC. in?

IMMUNIC, INC. (IMUX) operates in the Pharmaceutical Preparations industry.

What exchange does IMUX trade on?

IMMUNIC, INC. (IMUX) trades on the Nasdaq.

Where is IMMUNIC, INC. incorporated?

IMMUNIC, INC. is incorporated in DE.

When was IMMUNIC, INC. (IMUX)'s most recent SEC filing?

IMMUNIC, INC. (IMUX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.

What is IMUX's market cap?

IMMUNIC, INC. (IMUX) has a market capitalization of $653.44M as of 2026-06-30.

What is IMUX's EPS (earnings per share)?

IMMUNIC, INC. (IMUX)'s trailing twelve month EPS is $-2.62 as of 2026-06-30.

What is IMUX's ROE (return on equity)?

IMMUNIC, INC. (IMUX)'s trailing twelve month Return on Equity (ROE) is -138.17% as of 2026-06-30.

What is IMUX's ROA (return on assets)?

IMMUNIC, INC. (IMUX)'s trailing twelve month Return on Assets (ROA) is -101.15% as of 2026-06-30.

What is IMUX's EV/EBITDA?

IMMUNIC, INC. (IMUX)'s trailing twelve month EV/EBITDA is -4.23x as of 2026-06-30.

Wall Street's data.
Main Street's price.